EGFR and head and neck squamous cell carcinoma: The epidermal growth factor receptor (EGFR) inhibitor cetuximab in combination with chemotherapy (platinum and 5-fluorouracil; EXTREME) was, until recently, the first-line standard of care for patients with recurrent or metastatic (R/M) HNSCC in many countries, including Japan [5–9].